dexamethasone sustained-release (TLC599) / Taiwan Liposome Company, Endo 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
  • ||||||||||  dexamethasone sustained-release (TLC599) / Taiwan Liposome Company, Endo
    Enrollment closed, Trial completion date:  Episcleral Dexamethasone for Treatment of Macular Edema and Inflammatory Disorders of the Posterior Pole (clinicaltrials.gov) -  Nov 27, 2023   
    P1,  N=2, Active, not recruiting, 
    Cystoid edema showed better immediate response than spongy retinal thickening. Unknown status --> Active, not recruiting | Trial completion date: Sep 2020 --> Sep 2024
  • ||||||||||  dexamethasone sustained-release (TLC599) / Taiwan Liposome Company, Endo
    Enrollment closed, Trial completion date, Trial primary completion date:  A Phase I Study of Episcleral Dexamethasone for Treatment of Macular Edema (clinicaltrials.gov) -  Nov 26, 2023   
    P1,  N=1, Active, not recruiting, 
    Unknown status --> Active, not recruiting | Trial completion date: Sep 2020 --> Sep 2024 Unknown status --> Active, not recruiting | Trial completion date: Sep 2020 --> Sep 2024 | Trial primary completion date: Jun 2020 --> Sep 2024
  • ||||||||||  dexamethasone sustained-release (TLC599) / Taiwan Liposome Company, Endo
    A Phase 3 Study of Repeat Injection of TLC599 in Osteoarthritis of the Knee: Benefits to 52 Weeks (Room 6A-B; in person) -  Oct 24, 2023 - Abstract #ACRConvergence2023ACR_Convergence_4585;    
    These results provide additional information about the benefits of repeat steroid injection in OA of the knee and suggest that TLC599 may provide prolonged benefit and offer an alternative treatment for the management of OA knee pain. Change from Injection 1 Baseline in Average Daily Pain (ADP) Score of Patients Who Received the First Injection through Week 24 (N=504) and Patients Who Received a Repeat Injection from Week 24 through Week 52 (N=297)
  • ||||||||||  dexamethasone sustained-release (TLC599) / Taiwan Liposome Company, Endo
    Enrollment open, Trial completion date, Trial primary completion date:  A Phase 2, Open Label, PK Study of TLC599 in Subject With Osteoarthritis of the Knee (clinicaltrials.gov) -  Oct 10, 2023   
    P2,  N=102, Recruiting, 
    Change from Injection 1 Baseline in Average Daily Pain (ADP) Score of Patients Who Received the First Injection through Week 24 (N=504) and Patients Who Received a Repeat Injection from Week 24 through Week 52 (N=297) Completed --> Recruiting | Trial completion date: Jun 2022 --> Nov 2023 | Trial primary completion date: Jun 2022 --> Nov 2023
  • ||||||||||  dexamethasone sustained-release (TLC599) / Taiwan Liposome Company, Endo
    Trial completion:  A Phase 2, Open Label, PK Study of TLC599 in Subject With Osteoarthritis of the Knee (clinicaltrials.gov) -  Jul 8, 2022   
    P2,  N=93, Completed, 
    Completed --> Recruiting | Trial completion date: Jun 2022 --> Nov 2023 | Trial primary completion date: Jun 2022 --> Nov 2023 Active, not recruiting --> Completed
  • ||||||||||  dexamethasone sustained-release (TLC599) / Taiwan Liposome Company, Endo
    Trial completion date, Trial primary completion date:  A Phase 2, Open Label, PK Study of TLC599 in Subject With Osteoarthritis of the Knee (clinicaltrials.gov) -  Mar 8, 2022   
    P2,  N=90, Recruiting, 
    In participants with symptomatic knee osteoarthritis, TLC599 is a well-tolerated treatment that reduces pain and improves function for up to 24 weeks, a longer duration than that reported for existing IA treatments. Trial completion date: Feb 2022 --> Jun 2022 | Trial primary completion date: Feb 2022 --> Jun 2022
  • ||||||||||  Dextenza (dexamethasone punctal plug) / Ocular Therap, dexamethasone sustained-release (TLC599) / Taiwan Liposome Company
    Journal:  Dexamethasone Sustained-Release Intracanalicular Insert for Control of Postoperative Inflammation After Pars Plana Vitrectomy. (Pubmed Central) -  Sep 25, 2021   
    Overall, mean OCT CFT decreased in both groups; one patient had CME in the DII group, as compared to three in the topical steroid group (not statistically significant). The dexamethasone intracanalicular insert provided excellent safety and efficacy in control of postoperative inflammation following PPV in this retrospective case-matched study.
  • ||||||||||  dexamethasone sustained-release (TLC599) / Taiwan Liposome Company, Endo
    Enrollment open:  A Phase 2, Open Label, PK Study of TLC599 in Subject With Osteoarthritis of the Knee (clinicaltrials.gov) -  Apr 30, 2021   
    P2,  N=90, Recruiting, 
    The dexamethasone intracanalicular insert provided excellent safety and efficacy in control of postoperative inflammation following PPV in this retrospective case-matched study. Active, not recruiting --> Recruiting
  • ||||||||||  dexamethasone sustained-release (TLC599) / Taiwan Liposome Company, Endo
    Trial completion date, Trial primary completion date:  A Phase 2, Open Label, PK Study of TLC599 in Subject With Osteoarthritis of the Knee (clinicaltrials.gov) -  May 27, 2020   
    P2,  N=90, Active, not recruiting, 
    Recruiting --> Active, not recruiting Trial completion date: Dec 2020 --> Dec 2021 | Trial primary completion date: Dec 2020 --> Dec 2021
  • ||||||||||  dexamethasone sustained-release (TLC599) / Taiwan Liposome Company, Endo
    Trial completion date, Trial primary completion date:  EXCELLENCE: Extended and Controlled Release Liposomal Formulated Dexamethasone for Chronic Knee OA Pain (clinicaltrials.gov) -  Apr 7, 2020   
    P3,  N=500, Recruiting, 
    Trial completion date: Dec 2020 --> Dec 2021 | Trial primary completion date: Dec 2020 --> Dec 2021 Trial completion date: Sep 2021 --> Dec 2021 | Trial primary completion date: Aug 2021 --> Dec 2021
  • ||||||||||  dexamethasone sustained-release (TLC599) / Taiwan Liposome Company, Endo
    Enrollment closed, Trial completion date, Trial primary completion date:  A Phase 2, Open Label, PK Study of TLC599 in Subject With Osteoarthritis of the Knee (clinicaltrials.gov) -  Feb 25, 2020   
    P2,  N=90, Active, not recruiting, 
    Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | Trial completion date: Jan 2020 --> Dec 2020 | Trial primary completion date: Jan 2020 --> Dec 2020
  • ||||||||||  dexamethasone sustained-release (TLC599) / Taiwan Liposome Company, Endo
    Enrollment open:  A Phase 2, Open Label, PK Study of TLC599 in Subject With Osteoarthritis of the Knee (clinicaltrials.gov) -  Feb 26, 2019   
    P2,  N=90, Recruiting, 
    Comparison of significant cartilage damage by MOAKS between placebo- and TLC599-treated patients Figure 1. Not yet recruiting --> Recruiting
  • ||||||||||  dexamethasone sustained-release (TLC599) / Taiwan Liposome Company, Endo
    Enrollment closed:  Single-Dose Administration Trial of TLC599 in Osteoarthritis of the Knee (clinicaltrials.gov) -  Jul 28, 2016   
    P1/2,  N=40, Active, not recruiting, 
    Active, not recruiting --> Completed Recruiting --> Active, not recruiting